Clinical Trial Update: Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients [Phase 3]

View source ↗

Summary

Phase 3 trialUpdate comparing BCD-066 to Aranesp for anemia in chronic kidney disease patients has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease
• End Stage Renal Failure On Dialysis

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)
• BCD-066 (darbepoetin alfa biosimilar)

Snippet

Sponsor: Biocad | Conditions: Chronic Kidney Disease, End Stage Renal Failure on Dialysis | Phase 3 | Status: COMPLETED | Results posted: 2019-05-30